Friday, March 12, 2010

Not Your Father’s Drug Approval Process:
FDAAA and the Evolving Pharmaceutical Marketplace

MODERATOR

Judith Miller Jones
Director

SPEAKERS

Cole Werble
Senior Editor
The RPM Report
Founding Member, Prevision Policy
1055 Thomas Jefferson Street, NW
Suite 450A
Washington, DC 20007
Phone: 202/747-9478
E-mail: cole.werble@previsionpolicy.com

Cole Werble is a founding member of Prevision Policy, which provides health care policy analysis for business executives and investors. He has been covering pharmaceutical policy issues from Washington for 35 years. For 26 years, he headed the editorial team of 60 reporters and editors at FDC Reports (“The Pink Sheet” and other related publications). He was president of FDC for 24 of those years. Most recently, prior to founding Prevision Policy, he was senior executive editor of Elsevier Business Intelligence, the pharmaceutical news and analysis organization formed in March 2008 from the combination of FDC Reports and Windhover Information (IN VIVO and related publications). Mr. Werble was editor-in-chief of The RPM Report: Regulation, Policy and Market Access at Windhover. Mr. Werble is a frequent speaker at
industry events on pharmaceutical regulatory and reimbursement topics. He holds a BA degree (Phi Beta Kappa) from Williams College and an MA degree in English literature from the University of Chicago.

Michael McCaughan  
Senior Editor  
The RPM Report  
Founding Member, Prevision Policy  
1055 Thomas Jefferson Street, NW  
Suite 450A  
Washington, DC 20007  
Phone: 202/725-7283  
E-mail: michael.mccaughan@previsionpolicy.com

Michael McCaughan is a founding member of Prevision Policy. Previously, he was editor-in-chief of FDC-Windhover’s Biopharma Group, the leading publisher of news and information services for the pharmaceutical industry, including "The Pink Sheet," IN VIVO, The RPM Report, PharmAsia News, and The IN VIVO Blog. Mr. McCaughan speaks frequently on regulatory and policy developments affecting the biopharmaceutical industry. Mr. McCaughan joined "The Pink Sheet" in 1990 as a business reporter. He became assistant managing editor in 1993, managing editor in 1995, and editor-in-chief in 1996. He oversees an editorial staff of 35, and helped launch affiliated publications and on-line services, including Pharmaceutical Approvals Monthly, FDAAdvisoryCommittee.com, “The Pink Sheet” on the Web, “The Pink Sheet” DAILY, and The RPM Report. Mr. McCaughan is a summa cum laude graduate of Yale University.

David Dorsey, JD  
Acting Deputy Commissioner for Policy, Planning & Budget  
U.S. Food and Drug Administration  
10903 New Hampshire Avenue  
Building 1, Room 2314  
Silver Spring, MD 20993  
Phone: 301/796-4800  
E-mail: david.dorsey@fda.hhs.gov

David Dorsey, JD, is acting deputy commissioner for policy, planning and budget at the U.S. Food and Drug Administration (FDA). From April through August of this 2009, Mr. Dorsey was senior counselor to the commissioner at the FDA. From January 2001 to April 2009, he served as
a detaillee on Sen. Edward Kennedy's staff on the Senate Committee on Health, Education, Labor and Pensions, where he covered FDA matters. Prior to that time, he worked as an attorney in the agency's Office of Chief Counsel, where he focused on food labeling, dietary supplements, medical devices, and tobacco regulation. He graduated from Yale Law School in 1991 and has a master’s from Princeton and a BA degree from Haverford.

Peter Honig, MD
Managing Director
PH Regulatory and Medical Advisors, LLC
Philadelphia, PA
Phone: 267/664-4690
E-mail: honigpk@hotmail.com

Peter Honig, MD, received his baccalaureate, medical and public health degrees from Columbia University in New York. He has postgraduate training and is board-certified in internal medicine and clinical pharmacology and has authored numerous peer-reviewed publications and book chapters. He has held senior leadership positions at the U.S. Food and Drug Administration and Merck Research Laboratories and is the current PhRMA representative to the International Conference on Harmonization (ICH) Steering Committee and the co-chair of the ICH Global Cooperation Group (GCG), whose mission it is to promote regulatory harmonization in non-ICH countries and regions. Dr. Honig retains a faculty appointment at the Thomas Jefferson University School of Medicine, the Uniformed Services University of the Health Sciences, and is a current associate editor of *Clinical Pharmacology and Therapeutics*. He currently serves as a pharmaceutical consultant and is managing director of Peter Honig Regulatory and Medical Advisors, LLC.

Andrea Masciale, JD
Senior Director
Global Regulatory Affairs Strategic Policy and Support, The Americas Region Head
Johnson & Johnson Pharmaceuticals
1700 Rockville Pike, Suite 445
Rockville, MD 20852
Phone: 301/881-6974
E-mail: amascial@its.jnj.com

Andrea Masciale, JD, is senior director in the Global Regulatory Affairs Strategic Policy and Support organization of Johnson & Johnson Pharmaceuticals. Ms. Masciale leads a team that provides regulatory policy and health authority support in the Americas region, from Canada to Chile. In this role, she and her team seek to influence the development of key regulatory policies
that are expected to impact the pharmaceutical business through participation in trade association committees, leadership of and participation in multi-disciplinary working groups, and liaising with health authorities. Ms. Masciale also facilitates and supports product-based U.S. regulatory strategy development and issue resolution for Johnson & Johnson Pharmaceuticals.

Prior to joining Johnson & Johnson in 2003, Ms. Masciale served in the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). In CDER’s Office of Regulatory Policy, she served as regulatory counsel and finally the director of the Division of Information Disclosure Policy.

Ms. Masciale received a bachelor of arts degree in U.S. government from Georgetown University and a juris doctor degree from the College of William and Mary.